Coronavirus
Covid-19 autumn vaccine programme
Covid-19 autumn vaccine programme 13 September 2023 After the identification of a new Covid-19 variant, BA.2.86, health officials have brought forward this year’s autumn flu and Covid-19 vaccine programmes. Although BA.2.86 is not classified as a variant of concern, the UK Health Security Agency (UKHSA) have recommended speeding up the autumn vaccine programme as a…
Read MoreSupporting the kidney disease community: new results from PROTECT-V
Supporting the kidney disease community: new results from PROTECT-V 19 June 2023 Results from the PROTECT-V study presented at the European Renal Association in Milan on 16 June 2023 showed the study treatment, nasal niclosamide, does not offer protection against Covid-19 infection in at-risk kidney patients. Although these results are disappointing, there are many positive…
Read MoreUnderstanding the impact of the Covid-19 pandemic on kidney patient care
Understanding the impact of the Covid-19 pandemic on kidney patient care 25 May 2023 GP Dr Stuart Stewart has been awarded a Kidney Research UK grant of £250,000. The problem The Covid-19 pandemic has disrupted healthcare services in the UK, raising important questions about how well chronic kidney disease (CKD) has been detected, monitored and…
Read MoreNew study shows importance of Covid-19 vaccines in patients who have had a kidney transplant
New study shows importance of Covid-19 vaccines in patients who have had a kidney transplant 23 February 2023 The MELODY study, co-funded by Kidney Research UK, involved more than 28,000 immunocompromised patients across the UK, including those with solid organ transplants, patients with blood cancer and autoimmune diseases (including vasculitis and lupus). MELODY is the…
Read MoreNICE U-turn gives kidney patients much needed Covid-19 treatment
NICE U-turn gives kidney patients much needed Covid-19 treatment 22 February 2023 Kidney Research UK has welcomed the revised decision by the National Institute for Health and Care Excellence (NICE) to continue access to sotrovimab (Xevudy) for the treatment of kidney disease patients who are at high risk of progressing to severe Covid-19. What is…
Read MoreNICE process “not appropriate for a rapidly evolving virus”
NICE process “not appropriate for a rapidly evolving virus” 12 December 2022 We have submitted comments relating to NICE’s draft guidance on therapeutics for people with Covid-19, following the regulatory body’s draft decision to dramatically reduce the number of available treatments. We highlighted that the relevant evidence failed to consider the impact on high-risk patients…
Read MoreSupporting patients for fair access to anti-virals for Covid-19
Supporting patients for fair access to anti-virals for Covid-19 16 November 2022 The National Institute for Health and Care Excellence (NICE) has today published draft recommendations to drastically reduce the number of anti-viral treatment options available for people with Covid-19. With large numbers of people on immunosuppressants or with poor kidney function left exposed by…
Read MoreMaking vaccinations work better for patients on dialysis
Making vaccinations work better for patients on dialysis 20 July 2022 Professor Alan Salama and his colleagues at University College London are building on their previous finding that the immune systems of dialysis patients don’t work as well as they should. We are thrilled to be able to support his work on making vaccinations work…
Read MoreTrial to see if a tapeworm drug can protect vulnerable patients from Covid-19 expanded into India
Trial to see if a tapeworm drug can protect vulnerable patients from Covid-19 expanded into India 23 June 2022 PROTECT-V, a clinical trial which we helped to fund in its initial stages to find out whether a drug usually used to treat tapeworms can prevent Covid-19 infection in vulnerable kidney patients, has now expanded to…
Read MoreMELODY study update to include immunocompromised young people
MELODY study update to include immunocompromised young people 11 May 2022 We are pleased to share that we are funding an extension to the MELODY study to understand how well immunocompromised young people are protected against Covid-19 after vaccination. What is the MELODY study? Back in December, we shared details of the MELODY study that…
Read More